LIFECORE BIOMEDICAL, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value
LIFECORE BIOMEDICAL, INC. (LFCR) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value of $2.48 per share for the 3-month period ending 2024-08-25, per its 10-Q filed 2024-10-04.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue · last filed 2024-10-04
- LIFECORE BIOMEDICAL, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2024-08-25 was $2.48.
- LIFECORE BIOMEDICAL, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2024 was $3.91, a 15.68% increase from fiscal 2023.
- LIFECORE BIOMEDICAL, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2023 was $3.38, a 29.01% increase from fiscal 2022.
- LIFECORE BIOMEDICAL, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2022 was $2.62, a 10.55% increase from fiscal 2021.
- LIFECORE BIOMEDICAL, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2021 was $2.37, a 7.06% decline from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|
| 2024-08-25 | $2.48 10-Q · filed 2024-10-04 | |
| 2024-05-26 | $3.91 10-K · filed 2024-08-26 | |
| 2023-05-28 | $3.38 10-K · filed 2024-08-26 | |
| 2022-05-29 | $2.62 10-K · filed 2024-08-26 | |
| 2021-05-30 | $2.37 10-K · filed 2024-03-20 | |
| 2020-05-31 | $2.55 10-K/A · filed 2023-03-16 | |
| 2019-05-26 | $2.80 10-K · filed 2021-07-29 | |
| 2018-05-27 | $2.90 10-K · filed 2020-08-14 | |
| 2017-05-28 | $2.37 10-K · filed 2019-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |